QNRX on Nasdaq

Quoin Pharmaceuticals Ltd.

We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are.1

Price unavailable

Last updated Oct 19, 2026.

Overview

-$15.8MNet income, fiscal 20252

Compare with another stock.

  • TickerQNRX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAshburn, Virginia1
  • Incorporated inIsrael3
  • Business address42127 Pleasant Forest Court, Ashburn, Va 20148-73493
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). We have opened six clinical sites in the United States (“U.S.”) along with international sites that are being opened in the UK, Spain, France and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands and New Zealand. QRX003 is also b…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-3266.6%Return on equity5

Financial statements

Revenue6$0 in 2021
02019: $0$020192020: $0$020202021: $0$02021
Operating income78-$4.4M in 2020−33% since 2019
-$8.0M-$6.0M-$4.0M-$2.0M02019: -$6.5M-$6.5M20192020: -$4.4M-$4.4M2020−33%
Net income69-$21.5M in 2021+1275% since 2019
-$30.0M-$20.0M-$10.0M02019: -$1.6M-$1.6M20192020: -$2.1M-$2.1M2020+34%2021: -$21.5M-$21.5M2021+924%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-12-312024-12-31
General and administrative$6.5M$5.9M
Research and development$9.8M$3.6M
Total operating expenses$16.3M$9.5M
Unrealized gain-$4.0K-$7.5K
Realized and accrued interest income-$482.1K-$558.5K
Total other income-$486.1K-$566.0K
Net loss-$15.8M-$9.0M
Foreign currency translation-$613
Total other comprehensive loss-$613
Comprehensive loss-$15.8M-$9.0M

Compare Quoin Pharmaceuticals Ltd. with another company

Leadership

Who has led Quoin Pharmaceuticals Ltd., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Gordon Dunn2023–2024
  2. Sally Bridget Lawlor2025–now

Chief operating officer

  1. Denise P. Carter2023–now
2025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMichael Myers named Aug 31, 2022 to Sep 10, 202621
  • DirectorJames Bridget Culverwell named Oct 23, 2025 to Sep 10, 202621
  • DirectorJames Culverwell named Aug 31, 202222

Former names

  • Quoin Pharmaceuticals, Ltd.Oct 29, 2021 to Sep 1, 20263
  • Cellect Biotechnology Ltd.May 6, 2016 to Oct 15, 20213
  • Cellect Biomed Ltd.Apr 8, 2016 to Jul 7, 20163

Filings

316 filings to the SEC since October 2021: 5 annual reports, 11 quarterly reports, 64 major events, 67 insider forms, 29 large holders, 3 private raises, 137 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Oct 7, 2026SCHEDULE 13G/A EDGAR
  3. Oct 2, 2026DEF 14A EDGAR
  4. Sep 25, 2026EFFECT EDGAR
  5. Sep 25, 2026424B3 EDGAR
  6. Sep 22, 2026PRE 14A EDGAR
  7. Sep 22, 20268-K EDGAR
  8. Sep 18, 2026S-3 EDGAR
  9. Sep 10, 2026D EDGAR
  10. Sep 10, 20268-K EDGAR
  11. Sep 1, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Sep 1, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Sep 1, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Sep 1, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Aug 28, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Aug 28, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Aug 28, 20268-K EDGAR
  18. Aug 20, 20268-K EDGAR
  19. Aug 14, 20268-K EDGAR
  20. Aug 14, 202610-Q EDGAR

The 316 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 15 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Carter Denise P.Chief Operating OfficerBuy20,490$4.88$100.0KForm 4
Aug 31, 2026Myers MichaelChief Executive OfficerBuy20,490$4.88$100.0KForm 4
Aug 31, 2026Lawlor Sally BridgetChief Financial OfficerBuy10,244$4.88$50.0KForm 4
Aug 31, 2026Culverwell Anthony JamesDirectorBuy6,146$4.88$30.0KForm 4
Oct 14, 2025LANGER DENNISDirectorBuy15,152$8.49$128.6KForm 4
Dec 23, 2024Carter Denise P.Chief Operating OfficerBuy555,556$0.45$250.0KForm 4
Dec 23, 2024Myers MichaelChief Executive OfficerBuy555,556$0.45$250.0KForm 4
Dec 23, 2024Dunn GordonChief Financial OfficerBuy122,221$0.45$55.0KForm 4
Dec 23, 2024Culverwell Anthony JamesDirectorBuy100,000$0.45$45.0KForm 4
Sep 10, 2024Dunn GordonChief Financial OfficerBuy20,000$0.81$16.2KForm 4
Sep 9, 2024Dunn GordonChief Financial OfficerBuy8,856$0.79$7.0KForm 4
Sep 4, 2024Carter Denise P.Chief Operating OfficerBuy31,813$0.79$25.0KForm 4
Sep 4, 2024Myers MichaelChief Executive OfficerBuy37,094$0.77$28.5KForm 4
Sep 3, 2024Carter Denise P.Chief Operating OfficerBuy5,922$0.65$3.9KForm 4
Sep 3, 2024Myers MichaelChief Executive OfficerBuy800$0.62$496Form 4
Jun 7, 2024LANGER DENNISDirectorSale297$0.73$217Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 31, 2026Raised $50 million in a private offering of equity Form D: 33 investors so far Form D
  2. Oct 14, 2025Raised $105.3 million in a private offering of equity Form D: 27 investors so far Form D
  3. Aug 23, 2022Raised $193,537 in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Dauntless Investment Group, LLC214,987$1.0M1.8%+18,395
Ikarian Capital, LLC211,538$1.0M0.2%No change
Stonepine Capital Management, LLC199,486$965.5K0.7%+146,026
Millennium Management LLC112,323$543.6K0.0%+36,076
SummitTX Capital, L.P.100,300$485.5K0.0%No change
Woodline Partners LP76,446$370.0K0.0%−3,136
Aberdeen Group plc75,000$363.0K0.0%No change
Soleus Capital Management, L.P.72,730$352.0K0.0%No change
AIGH Capital Management LLC70,000$338.8K0.0%+19,000
Boothbay Fund Management, LLC59,838$289.6K0.0%No change
Velan Capital Investment Management LP32,372$156.7K0.1%−52,477
Barclays PLC21,469$103.9K0.0%+20,169
Birchview Capital, LP20,000$96.8K0.0%No change
XTX Topco Ltd15,006$72.6K0.0%New
Morgan Stanley8,000$38.7K0.0%+4,000
UBS Group AG6,772$32.8K0.0%+4,260
Rhumbline Advisers2,332$11.3K0.0%+811
GAMMA Investing LLC439$2.1K0.0%−1,281
SBI Securities Co., Ltd.355$1.7K0.0%+353

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35